{"address1": "2355 Westwood Boulevard", "address2": "Suite 139", "city": "Los Angeles", "state": "CA", "zip": "90064", "country": "United States", "phone": "310-948-2356", "website": "https://kairospharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-?\u00df pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors. It also develops ENV 105, an antibody that targets CD105/Endoglin, which expressed in tumor cells and surrounding cells; and ENV 205, an antibody that targets mitochondrial DNA. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. John S. Yu M.D., Ph.D.", "age": 60, "title": "CEO, Chairman & Secretary", "yearBorn": 1964, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas W. Samuelson CPA", "age": 64, "title": "Chief Financial Officer", "yearBorn": 1960, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neil A. Bhowmick Ph.D.", "age": 53, "title": "Chief Scientific Officer", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramachandran  Murali Ph.D.", "age": 64, "title": "Vice President of Research & Development", "yearBorn": 1960, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9362, "open": 0.915, "dayLow": 0.9158, "dayHigh": 0.9662, "regularMarketPreviousClose": 0.9362, "regularMarketOpen": 0.915, "regularMarketDayLow": 0.9158, "regularMarketDayHigh": 0.9662, "payoutRatio": 0.0, "forwardPE": -4.0, "volume": 19149, "regularMarketVolume": 19149, "averageVolume": 2388046, "averageVolume10days": 95270, "averageDailyVolume10Day": 95270, "bid": 0.9205, "ask": 0.9206, "bidSize": 11, "askSize": 29, "marketCap": 12604276, "fiftyTwoWeekLow": 0.851, "fiftyTwoWeekHigh": 4.0, "fiftyDayAverage": 1.22324, "twoHundredDayAverage": 1.4585, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 8744042, "profitMargins": 0.0, "floatShares": 4522711, "sharesOutstanding": 13700300, "sharesShort": 33043, "sharesShortPriorMonth": 41029, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.57512003, "heldPercentInstitutions": 0.02982, "shortRatio": 0.31, "shortPercentOfFloat": 0.0047, "impliedSharesOutstanding": 13700300, "bookValue": 0.259, "priceToBook": 3.5521235, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -2741000, "trailingEps": -0.21, "forwardEps": -0.23, "enterpriseToEbitda": -4.789, "52WeekChange": -0.6461538, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.92, "targetHighPrice": 9.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.5, "targetMedianPrice": 6.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 3217000, "totalCashPerShare": 0.25, "ebitda": -1826000, "totalDebt": 142000, "quickRatio": 1.924, "currentRatio": 2.836, "debtToEquity": 4.262, "returnOnAssets": -0.41709, "returnOnEquity": -3.75737, "freeCashflow": -3522125, "operatingCashflow": -2086000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "KAPA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "epsTrailingTwelveMonths": -0.21, "epsForward": -0.23, "epsCurrentYear": -0.1, "priceEpsCurrentYear": -9.2, "fiftyDayAverageChange": -0.30324, "fiftyDayAverageChangePercent": -0.24789903, "twoHundredDayAverageChange": -0.5385, "twoHundredDayAverageChangePercent": -0.36921495, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "marketState": "PRE", "regularMarketChangePercent": -1.7304, "regularMarketPrice": 0.92, "shortName": "Kairos Pharma, Ltd.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1726493400000, "preMarketChange": 0.00059998035, "preMarketChangePercent": 0.06521525, "preMarketPrice": 0.9206, "regularMarketChange": -0.0162, "regularMarketDayRange": "0.9158 - 0.9662", "fullExchangeName": "NYSE American", "averageDailyVolume3Month": 2388046, "fiftyTwoWeekLowChange": 0.069000006, "fiftyTwoWeekLowChangePercent": 0.081081085, "fiftyTwoWeekRange": "0.851 - 4.0", "fiftyTwoWeekHighChange": -3.08, "fiftyTwoWeekHighChangePercent": -0.77, "fiftyTwoWeekChangePercent": -64.61538, "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "preMarketTime": 1743598119, "regularMarketTime": 1743537560, "exchange": "ASE", "messageBoardId": "finmb_1832548029", "displayName": "Kairos Pharma", "trailingPegRatio": null}